New 3-substituted 4-(phenyl-N-alkyl)-piperazine and 4-(phenyl-N-alkyl)-piperidine
compounds of Formula (1), wherein X N, CH, or C, however X may only be C when the
compound comprises a double bond at the dotted line; R1 is OSO2CF3,
OSO2CH3, SOR3, SO2R3, COR3,
NO2, or CONHR3 and when X is CH or C R1 may also
be CF3, CN, F, Cl, Br, or I; R2 is a C1-C4
alkyl, an allyl, CH2SCH3, CH2CH2OCH3,
CH2CH2CH2F, CH2CF3, 3,3,3-trifluoropropyl,
4,4,4,-trifluorobutyl, or (CH2)R4; R3
is a C1-C3 alkyl CF3, or N(R2)2;
R4 is a C3-C6 cycloalkyl, 2-tetrahydrofurane or
3-tetra-hydrofurane, as well as pharmaceutically acceptable salts thereof are disclosed.
Also pharmaceutical compositions comprising the above compounds and methods wherein
the above compounds are used for treatment of disorders in the central nervous
system are disclosed
##STR1##
